Analysts Set Cellectis S.A. (NASDAQ:CLLS) PT at $6.33

Shares of Cellectis S.A. (NASDAQ:CLLS) have been assigned an average rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $6.3333.

Several equities research analysts recently commented on CLLS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st. Clear Str raised Cellectis to a “strong-buy” rating in a research report on Tuesday, December 23rd. Finally, Jefferies Financial Group began coverage on Cellectis in a research note on Tuesday, February 17th. They issued a “buy” rating and a $7.00 price target on the stock.

Cellectis Stock Performance

Shares of Cellectis stock opened at $3.50 on Friday. Cellectis has a 12 month low of $1.10 and a 12 month high of $5.48. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.49 and a quick ratio of 1.49. The business has a fifty day simple moving average of $3.92 and a two-hundred day simple moving average of $3.92.

Institutional Trading of Cellectis

Several institutional investors have recently bought and sold shares of CLLS. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after buying an additional 3,284,409 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 26,461 shares during the last quarter. Delaney Dennis R purchased a new stake in shares of Cellectis during the third quarter valued at approximately $68,000. B Group Inc. increased its position in shares of Cellectis by 0.8% during the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock valued at $9,352,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Cellectis in the 3rd quarter worth approximately $72,000. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.